Giant Cell Arteritis: Headache, Jaw Pain, Vision Risk, and Urgent Treatment

Why giant cell arteritis cannot wait

Giant cell arteritis matters because the first presentation may look ordinary: a new headache in an older adult, scalp tenderness while combing hair, or jaw fatigue with chewing. Yet the same arterial inflammation can abruptly compromise blood flow to the optic nerve. For patients, the key question is why clinicians treat before every test is back. For primary care physicians and internists, the question is how to recognize enough probability to start glucocorticoids while arranging confirmation and specialty care.

What is happening in the arteries

GCA is a granulomatous vasculitis, meaning immune cells inflame medium and large arteries, especially branches of the carotid artery and the aorta. Dendritic cells in the vessel wall activate T cells and macrophages, which release cytokines such as interleukin-6 and interferon gamma. The inflamed wall thickens, the lumen narrows, and ischemic symptoms appear. This biology explains why headache, jaw claudication, visual symptoms, limb claudication, and constitutional features can belong to one disease rather than separate problems.

The 2021 American College of Rheumatology and Vasculitis Foundation guideline emphasizes rapid treatment for suspected cranial GCA and supports vascular imaging or temporal artery biopsy to establish diagnosis. EULAR imaging recommendations also recognize ultrasound, MRI, CT angiography, and PET as useful depending on local expertise and whether cranial or large-vessel disease is suspected.

Clinical clues: headache, jaw pain, and vision risk

The headache of GCA is often new, persistent, and different from prior headaches. It may localize to the temples, but it can be diffuse or occipital. Scalp tenderness, temporal artery thickening, fever, weight loss, night sweats, shoulder or hip girdle pain from polymyalgia rheumatica, and elevated inflammatory markers all increase suspicion.

Jaw claudication is more specific than simple jaw pain. Patients describe aching or fatigue in the masseter muscles after repeated chewing, sometimes improving with rest, because inflamed arteries cannot meet muscle oxygen demand. The symptom is easy to miss if the question is phrased only as dental pain.

Visual risk is the reason GCA is treated as a same-day medical problem. Transient monocular vision loss, diplopia, amaurosis fugax, or new field loss can precede permanent anterior ischemic optic neuropathy. Once vision is lost, recovery is uncommon; treatment aims to protect the other eye and suppress vascular inflammation.

A concrete scenario

Consider a 74-year-old woman who reports two weeks of new temporal headache, tenderness when resting her head on a pillow, and fatigue in her jaw halfway through dinner. Her erythrocyte sedimentation rate and C-reactive protein are markedly elevated. Even before biopsy or ultrasound, this pattern is high enough risk that most clinicians would begin high-dose glucocorticoids, assess for visual symptoms immediately, and coordinate diagnostic testing without delaying therapy.

How diagnosis is confirmed

No single test rules GCA in or out. ESR and CRP are supportive, not definitive; a minority of patients have normal or only modestly abnormal markers. Temporal artery biopsy remains valuable because it can show granulomatous inflammation, intimal hyperplasia, and multinucleated giant cells, but skip lesions mean a negative biopsy does not fully exclude disease.

Ultrasound may show a halo sign, a darkened ring representing arterial wall edema. It is fast and noninvasive when expert operators are available. CT angiography, MR angiography, or PET can identify large-vessel involvement, which matters because aortic aneurysm, stenosis, or limb claudication may develop even when cranial symptoms improve.

Practical diagnostic elements

Typical evaluation includes:

• Age over 50 with a new localized headache or cranial ischemic symptom.
• Inflammatory markers, complete blood count, liver enzymes, and assessment for anemia or thrombocytosis.
• Temporal artery ultrasound, biopsy, or cross-sectional vascular imaging chosen by availability and phenotype.
• Baseline evaluation for glucocorticoid risks, including glucose, blood pressure, bone health, infection risk, and medication interactions.

Why treatment starts before certainty

The central clinical logic is asymmetric risk. A few days of glucocorticoids can slightly reduce biopsy sensitivity, although diagnostic yield often persists for at least one to two weeks. By contrast, a few days of untreated active cranial GCA can cost vision. Therefore, when pretest probability is substantial, treatment and testing proceed in parallel.

For patients without visual symptoms, high-dose oral prednisone is commonly used initially. For threatened or established vision loss, many guidelines and clinical practices favor intravenous methylprednisolone pulses before oral therapy, acknowledging that evidence is limited but the biologic stakes are high. Tapering then must balance relapse prevention against steroid toxicity.

Steroid-sparing therapy and monitoring

Tocilizumab, an interleukin-6 receptor inhibitor, changed routine management by reducing relapse and cumulative glucocorticoid exposure in the GiACTA trial, where weekly or every-other-week tocilizumab plus a prednisone taper produced more sustained remission than prednisone taper alone. The 2021 ACR/VF guideline conditionally recommends adding tocilizumab to glucocorticoids for many newly diagnosed patients, especially when relapse risk or steroid toxicity is a major concern.

Monitoring is nuanced because IL-6 blockade suppresses CRP and ESR, making symptoms and imaging more important. Clinicians track headache recurrence, jaw claudication, limb symptoms, vision changes, infections, lipid changes, liver enzymes, neutrophil counts, and gastrointestinal risk. Bone protection, vaccination review, and pneumocystis prophylaxis in selected high-risk steroid regimens may be considered.

Common misconception: normal labs exclude GCA

Normal inflammatory markers lower probability, but they do not eliminate it. Another misconception is that GCA is simply a headache disorder. It is a systemic vasculitis with cranial and large-vessel consequences. Conversely, not every headache in an older adult is GCA; the clinical pattern, examination, labs, and imaging must cohere.

Where evidence stands now

Current evidence supports glucocorticoids when cranial GCA is plausible, prompt confirmation with biopsy or imaging, and steroid-sparing therapy for selected patients. Uncertainty remains around optimal taper length, imaging surveillance intervals, and which biomarkers can measure disease activity when IL-6 signaling is blocked.